Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This source does not report specific results but compiles information on recent advancements in Advanced Therapy Medicinal Products and regenerative medicine from non-academic sources as of March 2026.

This review discusses the use, efficiency, and preparation methods of autologous platelet concentrates in wound healing and periodontal regeneration, but it reports no new clinical findings.

This study found that tribuloside, a flavonoid from Tribulus terrestris L., enhances melanin production in human melanocytes, zebrafish, and human skin samples without causing toxicity, potentially through inhibiting PDE to increase cAMP levels and promote the melanin biosynthesis pathway.

This review discusses advances in CRISPR/Cas9 variants and nanoformulations for cancer treatment, noting challenges and prospects for clinical application, but reports no new research results.

In this study, 13-cis-5S*,8S*-epidioxy-5,8-dihydroretinoic acid was found to be significantly more cytotoxic to cancer cell lines than other retinoic acid analogs evaluated.

This study reported that the Computational Analysis of Novel Drug Opportunities platform effectively uses integrated biological data, including side effects and pathways, to generate potential drug candidates for colon cancer and migraine disorders.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

In this report, researchers describe a 13-month-old with neurodevelopmental disorder NEDESBA, confirming a TRAPPC4 gene mutation as the cause after excluding biotinidase deficiency, highlighting the importance of molecular testing for accurate diagnosis in overlapping metabolic and genetic conditions.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This review discusses the potential benefits of nonantibiotic macrolides for treating inflammatory skin disorders and reports no new clinical results.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

In this study, a topical hair growth serum containing ingredients like procapil and redensyl was found to be safe and effective for subjects with androgenic alopecia, significantly improving hair density, thickness, and Anagen:Telogen ratio after 120 days, with no observed adverse effects.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study evaluated the long-term effects of combining autologous platelet-rich stroma injection with transanal advancement flap repair for cryptoglandular transsphincteric fistulas and found that it resulted in primary clinical closure and radiological healing in a high percentage of patients, with low recurrence rates.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.

This study explores the design of responsive drug carriers based on the tumor microenvironment to improve targeting and reduce side effects in cancer treatment, using a model of delivering curcumin with a responsive polymer carrier and evaluating potential errors due to cancer cell heterogeneity.

This review explores the potential of non-invasive photobiomodulation therapy for managing combat and traumatic soft tissue injuries, emphasizing its benefits, efficacy, and underlying mechanisms, but reports no new clinical results.

This study found that incorporating CTA2-BADG, a modified hair-rebonding compound, into damaged hair significantly improved surface morphology and tensile strength by using charge-conversion chemistry to enhance penetration into the hair shaft.

This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

This study found that in a mouse model of Leigh syndrome, rapamycin alters brain proteome and may extend survival by targeting protein kinase C.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

This study found that short-term treatment with ROCKi significantly increased keratinocyte stem cell proliferation without affecting their stemness, suggesting a potential safe approach for improving in vitro keratinocyte cultures for clinical applications.